Neumora Therapeutics reports favorable NMRA-215 toxicology results, plans IND in Q4 2026

Neumora Therapeutics, Inc.

Repeat 13-week rat toxicology study (162 animals) showed no unexpected adverse findings, resolving prior concerns from a study with 5 of 142 animals affected.
Company plans to submit IND for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease, in Q4 2026 and start Phase 1 by end of 2026.
NMRA-215 demonstrated class-leading weight loss in diet-induced obesity mouse model, including additive effects with semaglutide and potential for switch/maintenance.
For-cause audit of prior study revealed discrepancies; company believes prior adverse findings were not drug-related.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.